VIDEO: Treatment pipeline ‘highly active’ in psoriasis

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Pipeline still is highly active in spite of having a somewhat saturated market. And I think the consumers are driving a lot of these Pipeline drugs, so more non-steroidal agents are being investigated. And this is primarily out of concern for safety of long-term use.

So that's gonna continue to improve as these agents can be used for more than just psoriasis. But other diseases like atopic dermatitis, seborrheic dermatitis, et cetera. With newer oral agents like Deucravacitinib, or SOTYKTU, which is a, you know, JAK inhibitor that inhibits TYK2.

I think there'll be continued drugs that are similar in the JAK stat pathway that are oral, trying to target like more important pieces for psoriasis. And then also just comparative effectiveness is something that is being done more and more between biologic agents. So we have, you know, many biologics approved for psoriasis, but there are not that many studies comparing the IL-23 and IL-17 inhibitors. So those studies will continue to be done as we need to be able to discern which ones are more effective for which populations.